A CRO looking to build its manufacturing side business has a new parent after Keensight snaps up majority stake
Dutch CRO Symeres has looked to grow its manufacturing side business, recognizing the benefit of synergy in contract research and production. That dual mission caught the eye of Keensight Capital, a French investment firm who has decided to go all in and steer the ship.
Keensight on Tuesday said it would pick up a majority stake in Symeres from Gilde Healthcare. Symeres specializes in small molecules and provides R&D services from preclinical discovery to Phase I/II clinical stages of drug development alongside its manufacturing offerings. The company is growing, and Keensight will help the company grow its operation over the next few years, Keensight partner Amit Karna said.